Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs

Abstract Introduction Single intra-articular (IA) injections of poly(lactic-co-glycolic acid) (PLGA) microsphere-based triamcinolone acetonide extended-release (TA–ER; formerly FX006) demonstrated sustained, clinically relevant benefits in patients with knee osteoarthritis. The local effects of TA–E...

Full description

Bibliographic Details
Main Authors: Neil Bodick, Toni Williamson, Vibeke Strand, Becca Senter, Scott Kelley, Rogely Boyce, Ruth Lightfoot-Dunn
Format: Article
Language:English
Published: Adis, Springer Healthcare 2018-09-01
Series:Rheumatology and Therapy
Subjects:
Online Access:http://link.springer.com/article/10.1007/s40744-018-0125-3
id doaj-978adfc99c6e4324aa1882602b9e826a
record_format Article
spelling doaj-978adfc99c6e4324aa1882602b9e826a2020-11-24T22:12:33ZengAdis, Springer HealthcareRheumatology and Therapy2198-65762198-65842018-09-015247549810.1007/s40744-018-0125-3Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in DogsNeil Bodick0Toni Williamson1Vibeke Strand2Becca Senter3Scott Kelley4Rogely Boyce5Ruth Lightfoot-Dunn6Flexion Therapeutics, Inc.Flexion Therapeutics, Inc.Division of Immunology/Rheumatology, Stanford University School of MedicineFlexion Therapeutics, Inc.Flexion Therapeutics, Inc.Beechy Ridge ToxPath LLCCrucial Consulting, Inc.Abstract Introduction Single intra-articular (IA) injections of poly(lactic-co-glycolic acid) (PLGA) microsphere-based triamcinolone acetonide extended-release (TA–ER; formerly FX006) demonstrated sustained, clinically relevant benefits in patients with knee osteoarthritis. The local effects of TA–ER were assessed in normal canine knees in three nonclinical studies. Methods Knees were evaluated for up to 6 weeks or 9 months after a single injection of TA–ER (2.1/6.25/18.75 mg TA), or TA crystalline suspension (TAcs, 18.75 mg TA), and for up to 6 months after three injections (every 1 or 3 months) of TA–ER (6.25/18.75 mg TA) or TAcs (18.75 mg). Vehicle-diluent, blank microspheres, and untreated knees were used as controls. Plasma and synovial fluid (SF) TA concentrations and standard histopathological assessment of the synovium were conducted. Articular cartilage morphology was assessed via modified Mankin scoring. Results Plasma and SF concentrations indicated prolonged dose-dependent TA joint residency with TA–ER compared with TAcs. Effects in articular cartilage were dose- and time-dependent and consistent with known effects of corticosteroids in the normal knee. Loss of Safranin O staining occurred, indicative of a reduction in cartilage matrix proteoglycan, and recovered in a similar manner for TA–ER and TAcs across all studies. Structural lesions were infrequent and generally comparable in severity between TA–ER and TAcs but slightly higher in incidence for TA–ER. Focal/multifocal foreign-body responses (FBR) to PLGA were observed in the superficial layer of the synovium, peaking after 4–6 weeks, with significant recovery or complete resolution by month 6. Conclusions These findings suggest that the effects of IA injections of TA–ER on cartilage are predominantly transient, and comparable to those observed with TAcs in the normal canine knee joint. These mild effects in the normal joint differ from the beneficial effects observed with TA–ER and other corticosteroids in disease models. The synovial FBR to PLGA microspheres was focal and transient. Funding Flexion Therapeutics, Inc. Plain Language Summary Plain language summary available for this article.http://link.springer.com/article/10.1007/s40744-018-0125-3Biodegradable polymer drug carrierCartilageCorticosteroidIntra-articularMicrosphereTriamcinolone acetonide extended-release
collection DOAJ
language English
format Article
sources DOAJ
author Neil Bodick
Toni Williamson
Vibeke Strand
Becca Senter
Scott Kelley
Rogely Boyce
Ruth Lightfoot-Dunn
spellingShingle Neil Bodick
Toni Williamson
Vibeke Strand
Becca Senter
Scott Kelley
Rogely Boyce
Ruth Lightfoot-Dunn
Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs
Rheumatology and Therapy
Biodegradable polymer drug carrier
Cartilage
Corticosteroid
Intra-articular
Microsphere
Triamcinolone acetonide extended-release
author_facet Neil Bodick
Toni Williamson
Vibeke Strand
Becca Senter
Scott Kelley
Rogely Boyce
Ruth Lightfoot-Dunn
author_sort Neil Bodick
title Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs
title_short Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs
title_full Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs
title_fullStr Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs
title_full_unstemmed Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs
title_sort local effects following single and repeat intra-articular injections of triamcinolone acetonide extended-release: results from three nonclinical toxicity studies in dogs
publisher Adis, Springer Healthcare
series Rheumatology and Therapy
issn 2198-6576
2198-6584
publishDate 2018-09-01
description Abstract Introduction Single intra-articular (IA) injections of poly(lactic-co-glycolic acid) (PLGA) microsphere-based triamcinolone acetonide extended-release (TA–ER; formerly FX006) demonstrated sustained, clinically relevant benefits in patients with knee osteoarthritis. The local effects of TA–ER were assessed in normal canine knees in three nonclinical studies. Methods Knees were evaluated for up to 6 weeks or 9 months after a single injection of TA–ER (2.1/6.25/18.75 mg TA), or TA crystalline suspension (TAcs, 18.75 mg TA), and for up to 6 months after three injections (every 1 or 3 months) of TA–ER (6.25/18.75 mg TA) or TAcs (18.75 mg). Vehicle-diluent, blank microspheres, and untreated knees were used as controls. Plasma and synovial fluid (SF) TA concentrations and standard histopathological assessment of the synovium were conducted. Articular cartilage morphology was assessed via modified Mankin scoring. Results Plasma and SF concentrations indicated prolonged dose-dependent TA joint residency with TA–ER compared with TAcs. Effects in articular cartilage were dose- and time-dependent and consistent with known effects of corticosteroids in the normal knee. Loss of Safranin O staining occurred, indicative of a reduction in cartilage matrix proteoglycan, and recovered in a similar manner for TA–ER and TAcs across all studies. Structural lesions were infrequent and generally comparable in severity between TA–ER and TAcs but slightly higher in incidence for TA–ER. Focal/multifocal foreign-body responses (FBR) to PLGA were observed in the superficial layer of the synovium, peaking after 4–6 weeks, with significant recovery or complete resolution by month 6. Conclusions These findings suggest that the effects of IA injections of TA–ER on cartilage are predominantly transient, and comparable to those observed with TAcs in the normal canine knee joint. These mild effects in the normal joint differ from the beneficial effects observed with TA–ER and other corticosteroids in disease models. The synovial FBR to PLGA microspheres was focal and transient. Funding Flexion Therapeutics, Inc. Plain Language Summary Plain language summary available for this article.
topic Biodegradable polymer drug carrier
Cartilage
Corticosteroid
Intra-articular
Microsphere
Triamcinolone acetonide extended-release
url http://link.springer.com/article/10.1007/s40744-018-0125-3
work_keys_str_mv AT neilbodick localeffectsfollowingsingleandrepeatintraarticularinjectionsoftriamcinoloneacetonideextendedreleaseresultsfromthreenonclinicaltoxicitystudiesindogs
AT toniwilliamson localeffectsfollowingsingleandrepeatintraarticularinjectionsoftriamcinoloneacetonideextendedreleaseresultsfromthreenonclinicaltoxicitystudiesindogs
AT vibekestrand localeffectsfollowingsingleandrepeatintraarticularinjectionsoftriamcinoloneacetonideextendedreleaseresultsfromthreenonclinicaltoxicitystudiesindogs
AT beccasenter localeffectsfollowingsingleandrepeatintraarticularinjectionsoftriamcinoloneacetonideextendedreleaseresultsfromthreenonclinicaltoxicitystudiesindogs
AT scottkelley localeffectsfollowingsingleandrepeatintraarticularinjectionsoftriamcinoloneacetonideextendedreleaseresultsfromthreenonclinicaltoxicitystudiesindogs
AT rogelyboyce localeffectsfollowingsingleandrepeatintraarticularinjectionsoftriamcinoloneacetonideextendedreleaseresultsfromthreenonclinicaltoxicitystudiesindogs
AT ruthlightfootdunn localeffectsfollowingsingleandrepeatintraarticularinjectionsoftriamcinoloneacetonideextendedreleaseresultsfromthreenonclinicaltoxicitystudiesindogs
_version_ 1725803260858597376